DIMS Institute of Medical Science, Inc.

Developers of Medium-term Carcinogenesis Bioassays in the world. / Contract safety research facility.

Mission

HOME ≫ Company ≫

Company Profile

Company profile

Company name DIMS Institute of Medical Science, Inc.
Head office 64 Goura, Nishiazai, Azai-cho, Ichinomiya, Aichi 491-0113, Japan
Managing director Seiko Tamano
Tel +81-586-51-1201
Fax +81-586-51-5634
URL https://en.dims.co.jp/
Funding August 1978
Capital stock 28,800 thousand yen

History

 

1978 Daiyu-kai Institute of Medical Science was founded.
1980~ Initiated research on a medium-term liver carcinogenesis bioassay.
Developed and established optimum conditions of assay in collaboration with Nagoya City University.
Initiated research on medium-term multi-organ carcinogenesis bioassays.
1990~

Established medium-term liver and multi-organ carcinogenesis bioassays.

Initiated research on in vivo lung metastasis (lung metastasis of liver cancer) model and established.
2000

New research center was built.

Initiated research for models with transgenic rats (prostate cancer model).
2001

We participated SOT meeting in USA.

Improved medium-term carcinogenesis bioassay.
2003

The 25th anniversary symposium was held (January).

Patent acquisition of in vivo lung metastasis (lung metastasis of liver cancer) model to the United State of America (Pat. No. US 6,632,975 B1)
2004

The company name was changed to DIMS Institute of Medical Science, Inc.

(Old name: Daiyu-kai Institute of Medical Science, Inc.)

2005 The annex building completed.
2007

The 30th anniversary symposium was held (November).

Initiated toxicity study with a repeated intratracheal administration.
Applied for patent of DIMS-type sonde for intratracheal administration.
2008

Initiated research on developing short-term carcinogenicity with rasH2 transgenic mice.

Chemical analysis section was established.

2013

Initiated contract research of 26-week carcinogenicity study using rasH2 transgenic mice.

Acquisition of evaluation and verification for welfare animal experiments by the external certification organization, the Center for Accreditation of Laboratory Animal Care and Use, Japan Health Sciences Foundation.
2016 Initiated contract research of ultra-short-term skin carcinogenesis bioassay using rasH2 transgenic mice.

Japanese

Medium-term Carcinogenesis Bioassay/Safety Assessment for Developing Products

DIMS Institute of Medical Science, Inc.

64 Goura, Nishiazai,
Azai-cho, Ichinomiya,
Aichi 491-0113, Japan

Tel: +81-586-51-1201
Fax: +81-586-51-5634

Company Profile

Mobile site

DIMS Institute of Medical Science, Inc.スマホサイトQRコード

Access to the mobile site of DIMS. from this QR code.